MEA Cancer Screening Market (2018-2023)
The report is sent in 5-10 business days after order is placed.
Middle East and Africa cancer screening market
The Middle East and Africa (MEA) cancer screening market is growing at a very slow rate. The MEA market is projected to reach USD 50.61 Bn by 2023, at a compound annual growth rate (CAGR) of 11.5% during the forecast period (2018-2023).The United Arab Emirates (UAE), Saudi Arabia and Kuwait are expected to drive the MEA cancer screening market while Africa will witness a moderate growth. Due to limited availability, the MEA occupies the least share in the market.
By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. Independent physicians and clinics along with hospitals will witness an optimistic growth during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Laboratory, biopsy and genetic tests will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Lung, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into UAE, Saudi Arabia and the rest of the MEA.
Key growth factors
The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.
Threats and key players
The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the MEA cancer screening market are Thermo Fisher Scientific, GE Healthcare, Siemens Healthcare, Roche Diagnostics and Illumina Inc.
What is covered in the report?
1. Overview of the MEA cancer screening market.
2. Market drivers and challenges in the MEA cancer screening market.
3. Market trends in the MEA cancer screening market.
4. Historical, current and forecasted market size data for MEA market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the MEA market segmentation based on type of end-user (hospitals, laboratory, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries and others (other parts of MEA) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the MEA market.
Why buy?
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
Middle East and Africa cancer screening market
The Middle East and Africa (MEA) cancer screening market is growing at a very slow rate. The MEA market is projected to reach USD 50.61 Bn by 2023, at a compound annual growth rate (CAGR) of 11.5% during the forecast period (2018-2023).The United Arab Emirates (UAE), Saudi Arabia and Kuwait are expected to drive the MEA cancer screening market while Africa will witness a moderate growth. Due to limited availability, the MEA occupies the least share in the market.
By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. Independent physicians and clinics along with hospitals will witness an optimistic growth during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Laboratory, biopsy and genetic tests will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Lung, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into UAE, Saudi Arabia and the rest of the MEA.
Key growth factors
The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.
Threats and key players
The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the MEA cancer screening market are Thermo Fisher Scientific, GE Healthcare, Siemens Healthcare, Roche Diagnostics and Illumina Inc.
What is covered in the report?
1. Overview of the MEA cancer screening market.
2. Market drivers and challenges in the MEA cancer screening market.
3. Market trends in the MEA cancer screening market.
4. Historical, current and forecasted market size data for MEA market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the MEA market segmentation based on type of end-user (hospitals, laboratory, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries and others (other parts of MEA) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the MEA market.
Why buy?
- Understand the demand for cancer screening market to determine the viability of the market.
- Understand the country-specific market size and observations for each segment.
- Develop strategies based on the drivers, trends and highlights for each of the segments.
- Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
- Recognize the key competitors of this market and respond accordingly.
- Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
- Define the competitive positioning by comparing the products and services compared with the key players in the market
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1: EXECUTIVE SUMMARY
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: THE MIDDLE EAST AND AFRICA CANCER SCREENING MARKET – MARKET OVERVIEW
2.1. The MEA market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. The MEA – market drivers and challenges
2.3. Value chain analysis – cancer screening market
2.4. Porter’s five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
2.5. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration
CHAPTER 3. THE UAE CANCER SCREENING MARKET
3.1. The UAE market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
3.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges
CHAPTER 4. SAUDI ARABIA CANCER SCREENING MARKET
4.1. Saudi Arabia market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
4.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type of application type (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges
CHAPTER 5. OTHERS (THE REST OF MEA) CANCER SCREENING MARKET
5.1. Others (the rest of MEA) market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
5.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. Thermo Fisher Scientific
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Siemens Healthineers
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. GE Healthcare
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Roche Diagnostics
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Illumina Inc.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: THE MIDDLE EAST AND AFRICA CANCER SCREENING MARKET – MARKET OVERVIEW
2.1. The MEA market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. The MEA – market drivers and challenges
2.3. Value chain analysis – cancer screening market
2.4. Porter’s five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
2.5. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration
CHAPTER 3. THE UAE CANCER SCREENING MARKET
3.1. The UAE market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
3.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges
CHAPTER 4. SAUDI ARABIA CANCER SCREENING MARKET
4.1. Saudi Arabia market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
4.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type of application type (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges
CHAPTER 5. OTHERS (THE REST OF MEA) CANCER SCREENING MARKET
5.1. Others (the rest of MEA) market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
5.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. Thermo Fisher Scientific
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Siemens Healthineers
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. GE Healthcare
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Roche Diagnostics
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Illumina Inc.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
